Form 4: Twist Bioscience CAO Sells Shares

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported sales of company common stock totaling 7,175 shares in early February 2026.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reported two sales of common stock.
• On February 3, 2026, 175 shares were sold at $46.576 per share. This transaction was a 'sell to cover' to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and was mandated by the Issuer's equity incentive plans, not a discretionary trade.
• On February 4, 2026, an additional 7,000 shares were sold at a weighted average price of $45.648 per share, with individual sales ranging from $45.61 to $45.78.
• Following these transactions, Mr. Werner directly beneficially owns 58,738 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing. While the 'sell to cover' is a routine event, the additional sale of 7,000 shares by a key executive, without a stated non-discretionary reason, could be interpreted with slight caution by the market.

Positives

• The sale of 175 shares was a non-discretionary 'sell to cover' transaction, a standard procedure for satisfying tax obligations upon RSU vesting, indicating the realization of equity compensation.

Negatives

• The sale of 7,000 shares by a Chief Accounting Officer, without an explicit non-discretionary reason stated in the filing, could be perceived by some investors as a signal, although the filing does not provide further context for this specific sale.

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking officers like a Chief Accounting Officer, are routinely monitored by investors for insights into management's perception of the company's valuation or future prospects. While 'sell to cover' transactions are common and non-discretionary, other sales are often scrutinized more closely for potential implications on market sentiment.

Related Party Transactions

• The sale of 175 shares was mandated by the Issuer's equity incentive plans to cover tax withholding obligations, representing a transaction with the company's plan administrator.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially influencing sentiment, though the impact is likely minor given the size relative to total shares outstanding and the routine nature of some of the sales.

Key Dates

Recommendation

The filing reports routine insider sales, including a non-discretionary 'sell to cover' for tax obligations and a separate sale of 7,000 shares. While insider sales are generally monitored, these transactions alone are not substantial enough to warrant a change in investment thesis for a seasoned investor. The company's fundamentals and broader market conditions would be more significant drivers for a 'buy' or 'sell' decision, thus a 'hold' recommendation is appropriate based solely on this Form 4.

Keywords

Twist Bioscience, TWST, Insider Trading, Form 4, Stock Sale, Robert F. Werner, Chief Accounting Officer, Equity Compensation, Restricted Stock Units